TY - JOUR
T1 - Elevated polygenic burden for autism is associated with differential DNA methylation at birth
AU - iPSYCH-Broad ASD Group
AU - Hannon, Eilis
AU - Schendel, Diana
AU - Ladd-Acosta, Christine
AU - Grove, Jakob
AU - Hansen, Christine Søholm
AU - Andrews, Shan V.
AU - Hougaard, David Michael
AU - Bresnahan, Michaeline
AU - Mors, Ole
AU - Hollegaard, Mads Vilhelm
AU - Bækvad-Hansen, Marie
AU - Hornig, Mady
AU - Mortensen, Preben Bo
AU - Børglum, Anders D.
AU - Werge, Thomas
AU - Pedersen, Marianne Giørtz
AU - Nordentoft, Merete
AU - Buxbaum, Joseph
AU - Daniele Fallin, M.
AU - Bybjerg-Grauholm, Jonas
AU - Reichenberg, Abraham
AU - Mill, Jonathan
AU - Agerbo, Esben
AU - Als, Thomas D.
AU - Belliveau, Rich
AU - Bækved-Hansen, Marie
AU - Cerrato, Felecia
AU - Christensen, Jane
AU - Chambert, Kimberly
AU - Churchhouse, Claire
AU - Daly, Mark
AU - Demontis, Ditte
AU - Dumont, Ashley
AU - Goldstein, Jacqueline
AU - Hansen, Christine
AU - Hauberg, Mads
AU - Hougaard, David
AU - Howrigan, Daniel
AU - Huang, Hailiang
AU - Maller, Julian
AU - Martin, Alicia
AU - Martin, Joanna
AU - Mattheisen, Manuel
AU - Moran, Jennifer
AU - Neale, Benjamin
AU - Nyegaard, Mette
AU - Pallsen, Jonatan
AU - Palmer, Duncan
AU - Pedersen, Carsten
AU - Pedersen, Marianne
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/3/28
Y1 - 2018/3/28
N2 - Background: Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder characterized by deficits in social communication and restricted, repetitive behaviors, interests, or activities. The etiology of ASD involves both inherited and environmental risk factors, with epigenetic processes hypothesized as one mechanism by which both genetic and non-genetic variation influence gene regulation and pathogenesis. The aim of this study was to identify DNA methylation biomarkers of ASD detectable at birth. Methods: We quantified neonatal methylomic variation in 1263 infants-of whom ~ 50% went on to subsequently develop ASD-using DNA isolated from archived blood spots taken shortly after birth. We used matched genotype data from the same individuals to examine the molecular consequences of ASD-associated genetic risk variants, identifying methylomic variation associated with elevated polygenic burden for ASD. In addition, we performed DNA methylation quantitative trait loci (mQTL) mapping to prioritize target genes from ASD GWAS findings. Results: We identified robust epigenetic signatures of gestational age and prenatal tobacco exposure, confirming the utility of DNA methylation data generated from neonatal blood spots. Although we did not identify specific loci showing robust differences in neonatal DNA methylation associated with later ASD, there was a significant association between increased polygenic burden for autism and methylomic variation at specific loci. Each unit of elevated ASD polygenic risk score was associated with a mean increase in DNA methylation of - 0.14% at two CpG sites located proximal to a robust GWAS signal for ASD on chromosome 8. Conclusions: This study is the largest analysis of DNA methylation in ASD undertaken and the first to integrate genetic and epigenetic variation at birth. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with disease, and of using mQTL to refine the functional and regulatory variation associated with ASD risk variants.
AB - Background: Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder characterized by deficits in social communication and restricted, repetitive behaviors, interests, or activities. The etiology of ASD involves both inherited and environmental risk factors, with epigenetic processes hypothesized as one mechanism by which both genetic and non-genetic variation influence gene regulation and pathogenesis. The aim of this study was to identify DNA methylation biomarkers of ASD detectable at birth. Methods: We quantified neonatal methylomic variation in 1263 infants-of whom ~ 50% went on to subsequently develop ASD-using DNA isolated from archived blood spots taken shortly after birth. We used matched genotype data from the same individuals to examine the molecular consequences of ASD-associated genetic risk variants, identifying methylomic variation associated with elevated polygenic burden for ASD. In addition, we performed DNA methylation quantitative trait loci (mQTL) mapping to prioritize target genes from ASD GWAS findings. Results: We identified robust epigenetic signatures of gestational age and prenatal tobacco exposure, confirming the utility of DNA methylation data generated from neonatal blood spots. Although we did not identify specific loci showing robust differences in neonatal DNA methylation associated with later ASD, there was a significant association between increased polygenic burden for autism and methylomic variation at specific loci. Each unit of elevated ASD polygenic risk score was associated with a mean increase in DNA methylation of - 0.14% at two CpG sites located proximal to a robust GWAS signal for ASD on chromosome 8. Conclusions: This study is the largest analysis of DNA methylation in ASD undertaken and the first to integrate genetic and epigenetic variation at birth. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with disease, and of using mQTL to refine the functional and regulatory variation associated with ASD risk variants.
KW - Autism
KW - Birth
KW - DNA methylation
KW - DNA methylation quantitative trait loci (mQTL)
KW - Epigenome-wide association study (EWAS)
KW - Genetics
KW - Genome-wide association study (GWAS)
KW - Neonatal
KW - Polygenic risk score
KW - Prenatal smoking
UR - http://www.scopus.com/inward/record.url?scp=85044353251&partnerID=8YFLogxK
U2 - 10.1186/s13073-018-0527-4
DO - 10.1186/s13073-018-0527-4
M3 - Article
C2 - 29587883
AN - SCOPUS:85044353251
SN - 1756-994X
VL - 10
JO - Genome Medicine
JF - Genome Medicine
IS - 1
M1 - 19
ER -